Skip to main content
Premium Trial:

Request an Annual Quote

SpeeDx Inks Benelux Distribution Agreement With Goffin Molecular

NEW YORK (GenomeWeb) – Australia's SpeeDx said today that it has signed a distribution agreement with Goffin Molecular Technologies, a Netherlands-based molecular diagnostics firm.

Under the agreement, Goffin will distribute SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR product lines in Benelux.

"The timing of this agreement aligns well with our near-term European launch plans to offer our PlexPCR infectious disease and ResistancePlus antibiotic resistance multiplex qPCR tests in the Benelux market," Colin Denver, vice president of sales and marketing for SpeeDx, said in a statement. "Based on Goffin's track record, we're confident that this collaboration will rapidly increase our European presence in targeted molecular diagnostic markets."

SpeeDx is a privately owned company that provides multiplex qPCR and isothermal amplification solutions for clinical diagnostics. It is initially focusing its ResistancePlus pipeline on sexually transmitted infections such as Mycoplasma genitalium and Neisseria gonorrhoeae.

Goffin Molecular Technologies offers a comprehensive line of molecular diagnostic products, including automation, consumables, reagents, instruments and pre-analytical treatments, in the areas of infectious diseases and genetics.